nature portfolio

Corresponding author(s): Xiongfeng Dai

Last updated by author(s): Oct 8, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics

For all statistical analyses, co	nfirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed	
The exact sample si	ze (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on who	ether measurements were taken from distinct samples or whether the same sample was measured repeatedly
X '	s) used AND whether they are one- or two-sided ould be described solely by name; describe more complex techniques in the Methods section.
A description of all	covariates tested
A description of any	assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of AND variation (e.g.	the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	testing, the test statistic (e.g. <i>F, t, r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted values whenever suitable.
For Bayesian analys	is, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and	complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect	sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
·	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>			
Data collection	No software was used for data collection.		
Data analysis	General plots of data are performed by Graphpad prism 8.0; Mass spec data was analyzed by Maxquant v1.6.15.0.		

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD053191 for XA1826LQ project and PXD053195 for XA1827LQ project. The core data of proteomics related to Figure 4; Figure 7 are also provided in the supplementary data 1-7. Source data are provided with the paper.

Research involving human participants, their data, or biological material

Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation), and sexual orientation and race, ethnicity and racism.

Reporting on sex and gender	n/a
Reporting on race, ethnicity, or other socially relevant groupings	n/a
Population characteristics	n/a
Recruitment	n/a
Ethics oversight	n/a

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

	-	
x	Life sciences	Be

Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No statistical methods were used to predetermine sample sizes. As many as replicates as possible were done for the papers. Most key data such as growth rates, lacZ reporter activities have generally been repeated for at least 3 times. See the figure legends for detailed number of replicates. The deviations between biological replicates are small and are thus highly reproducible and sufficient to draw solid conclusions.
Data exclusions	No data were excluded.
Replication	As many as replicates as possible were done for the papers. The replication times differs from experiments to experiments (at least 3 biological replicates in most cases for key data such as growth rates, lacZ reporter assay etc) and have been listed in the figures legends. All attempts at replication were successful and the results are highly reproducible.
Randomization	This is not relevant as it is a non-clinical related study, we did not take the randomization into the experimental design. Our data are grouped under clear categories such as genotype, nutrients etc.
Blinding	Data collection followed the exact same predetermined protocols throughout the whole study, so no blinding was performed. Our data are grouped under clear categories such as genotype, nutrients etc.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Methods	
n/a Involved in the study		n/a	Involved in the study
×	Antibodies	×	ChIP-seq
×	Eukaryotic cell lines	×	Flow cytometry
×	Palaeontology and archaeology	×	MRI-based neuroimaging
×	Animals and other organisms		
×	Clinical data		
×	Dual use research of concern		
×	Plants		

Plants

Seed stocks	(n/a			
Novel plant genotypes	n/a			
Authentication	n/a			